Sky Medical Receives FDA Clearance to Market Its geko Device For Venous Insufficiency And Ischemia

Medical devices company, Sky Medical Technology Ltd, received U.S. Food and Drug Administration ...

PRNewswire photo

Medical devices company, Sky Medical Technology Ltd, received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the geko™ device for increasing microcirculatory blood flow in lower limb soft tissue of patients with venous insufficiency and/or ischemia.

Read more: Monash University Researchers Develop Wearable Blood Pressure Monitor

The geko device is the first electrical neuromuscular stimulator of its kind to be cleared for increasing microcirculatory blood flow and adds to Sky's prior FDA clearances for edema reduction and for stimulation of the calf muscles to prevent venous thrombosis (blood clots) in both surgical and non-surgical patients.

Venous insufficiency and ischemia relate to reduced blood flow in the veins and arteries. This can lead to lower extremity edema, skin changes, and discomfort. Venous insufficiency can progress to chronic venous insufficiency (CVI), a serious condition attributed to diminished quality of life and loss of work productivity. In most cases, the cause is incompetent valves. Each year approximately 150,000 new patients are diagnosed with chronic venous insufficiency, and nearly $500 million is used in the care of these patients. If venous insufficiency and ischemia are left untreated, progressive CVI can lead to post-phlebitic syndrome and venous leg ulcers, the company said in a press release.

Three recently published studies, two led by Das, and the other led by Bosanquet demonstrate geko device-generated microcirculatory blood flow increase in the lower limbs of patients with venous insufficiency and ischemia. Both studies measured the increase using Laser Speckle Contrast Imaging, a non-invasive technique that measures blood flow.

CEO and Founder Bernard Ross said, "Achieving this latest 510(k) clearance is a significant milestone for Sky that will allow us to initiate a controlled market release of the geko device, to address venous insufficiency and ischemia in the first instance – a therapy area sorely in need of innovation. With this 510(k) and in partnership with leading US clinicians we can now press ahead to redefine the way vascular-related conditions can be treated."

The geko device is a non-invasive, easy-to-use, wearable therapy device. The size of a wristwatch and worn at the knee, the disposable device gently stimulates the common peroneal nerve activating the calf and foot muscle pumps, resulting in increased blood flow in the deep veins of the calf, at a rate equal to 60%6 of walking without a patient having to move. The device operates without external pressure to the leg and allows complete mobility.

Read more: This “Smart Stent” Can Monitor Blood Flow and Detect Narrowing of Artery

The company is headquartered in the UK and backed by leading international investors in both healthcare and technology. The company is in the process of submitting further FDA 510(k) applications to expand its claims related to blood flow increase to address venous insufficiency.

About Sky Medical Technology Ltd and Firstkind Ltd

Sky Medical Technology, the parent of Firstkind Ltd, is a UK-based medical devices company. Through its innovative mechanism of non-invasive neuromuscular electrostimulation, Sky has developed a ground-breaking NMES technology platform, OnPulse, embedded in its industry-leading product, the geko device. The company develops a range of products tailored to the needs of different medical application areas, selling both direct and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include DVT prevention, the treatment and reduction of edema, and venous insufficiency. The goal in each pathway is to partner with healthcare professionals to improve clinical outcomes and patient care whilst saving health system resources.

Sam Draper
December 20, 2021

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Flexible, Antibacterial Conductive Hydrogel-ePatch For Accelerated Wound Healing

A team from the Terasaki Institute has developed a smart flexible electric patch (ePatch).

December 2022: Quad Industries

Screen-print electrodes and biosensors increase their scope of application!

Ways AI Will Be Used in Healthcare in 2024

Digital health industry leaders revealed where they believe AI will have the biggest impact.

How Big Tech Companies Are Disrupting the Digital Health Market

Big tech companies have been trying to gain a firm foothold in the digital health market.
Discover more